Respiratory technology company Rhinomed (ASX:RNO) is pleased to announce that it has been advised by Sigma Healthcare that Mute sleep technology will form part of the 2017 core range for the Amcal and Guardian pharmacy brands. This adds to Rhinomed’s existing Sigma relationship which saw Discount Drug Stores stock Mute, meaning the majority of Sigma … Read more
Rhinomed (ASX:RNO) a leader in nasal respiratory technology, today released the Appendix 4E Preliminary Final Report Read a full copy of the report here.
Rhinomed (ASX:RNO) a leader in nasal respiratory technology, today announced a pivotal year of growth and milestone achievement. The company can report record recognised revenues for FY18 Q4 of $874k – a 71% increase over FY18 Q3 and totalling $2.13m for the full FY18, up 24% on FY17. This came off the back of another … Read more
RHINOMED & US BASED COLUMBIA CARE TO DEVELOP NASALLY DELIVERED DOSE CONTROLLED CANNABIS BASED MEDICINES June 21, 2018, Melbourne, Australia. Melbourne based nasal respiratory company Rhinomed (ASX:RNO) is pleased to advise investors that it has signed a non-binding term sheet with Columbia Care LLC (“Columbia Care”) to license Rhinomed’s nasal platform for the delivery of medical … Read more
MUTE EXPANDS RANGING IN LEADING US PHARMACY – OVER 1100 NEW STORES ADDED June 19, 2018, Melbourne, Australia. Australian nasal and respiratory technology company Rhinomed (ASX:RNO) is pleased to advise investors that it has expended its relationship with one of America’s largest pharmacy retailer – CVS. The Company has now received initial purchase orders confirming that Mute … Read more
HALF YEARLY REPORT AND ACCOUNTS February 28, 2018. Melbourne, Australia. Rhinomed (ASX:RNO or “the Company) releases its half yearly report and accounts. Read a full copy of the report here.
